Navigation Links
Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results

REHOVOT, Israel and JERSEY CITY, New Jersey, August 12 /PRNewswire-FirstCall/ -- Rosetta Genomics (Nasdaq: ROSG), today announced it will release first quarter financial results on August 19, 2008, before the U.S. markets open. Rosetta Genomics will host a conference call with a simultaneous webcast to discuss these results at 8:30 a.m. ET on Tuesday, August 19.

To access the live conference call, U.S. and Canadian participants may dial 1-866-966-5335; international participants may dial +44-20-3023-4460. To access the 24-hour audio replay, U.S. and Canadian participants may dial 1-866-583-1035; international participants may dial 44-20-8196-1998. The access code for the replay is 181543#. The replay will be available until August 26, 2008.

A live audio webcast of the call will also be available on the "Investors" section of the company's website, An archived webcast will be available on the Company's website approximately two hours after the event, and will be archived for 30 days thereafter.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNAs. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications. The first microRNA diagnostic test applying Rosetta Genomics' technology has been approved for clinical use by the State of New York, and the company expects it will be launched by licensed clinical laboratories in the United States in 2008.


Media & Investors

Ron Kamienchick

T: 1-(646)-509-1893


SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
2. Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference
3. Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer
4. Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
5. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
6. /C O R R E C T I O N -- Rosetta Genomics Ltd/
7. Rosetta Genomics Reports First Quarter 2008 Financial Results
8. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
9. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
10. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
11. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):